bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
BIAFSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes private placement and warrant inducement transaction for approximately $1.2 million in gross proceeds
bioAffinity Technologies Reports Second Quarter 2025 Results
BIAFSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports Q2 2025 results; CyPath Lung revenues up 62% year-over-year in first six months of 2025
WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
BIAFJERSEY CITY, N.J., Aug. 13, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive...
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
BIAFSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of private placement and warrant inducement transaction
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
BIAFSAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a significant surge in commercial sales of CyPath® Lung with back-to-back record monthly sales in June and July.
12 Health Care Stocks Moving In Thursday's After-Market Session
BIAFbioAffinity Technologies Secures U.S. Patent For Novel siRNA Composition Targeting CD320 And LRP2 Cell Receptors To Selectively Kill Cancer Cells, Advancing Research On Topical Treatments For Skin Cancers And Expanding Therapeutic Portfolio Covering Lung,
BIAFbioAffinity Technologies Announces It Has Been Awarded New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics
BIAFbioAffinity Technologies Q1 EPS $(0.16), Inline, Sales $1.85M Miss $2.11M Estimate
BIAFbioAffinity Technologies Announces Release Of White Paper Titled CyPath® Lung in Practice: Cases 1-4,
BIAFCrude Oil Rises Sharply; US Trade Deficit Widens In March
BIAFDow Falls Over 250 Points; Marriott Posts Upbeat Earnings
BIAFbioAffinity Technologies Announces Pricing Of $3.25M Offering Of 10,156,250 Shares Of Our Common Stock, Together With Warrants To Initially Purchase Up To 15,234,375 Shares Of Common Stock; The Combined Price For Each Share Of Common Stock And Accompanyin
BIAFBioAffinity Technologies Implements Key Efficiency Measures For Its Flagship Product, CyPath Lung, Noninvasive Test For Detection Of Lung Cancer
BIAF12 Health Care Stocks Moving In Tuesday's Intraday Session
BIAFWhat's Going On With BioAffinity Shares Tuesday?
BIAFBioAffinity shares are moving higher on Tuesday after the company reported 2024 fiscal-year earnings, showing multiple year-over-year increases.
Maxim Group Downgrades bioAffinity Technologies to Hold
BIAF12 Health Care Stocks Moving In Tuesday's Pre-Market Session
BIAFWhy PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
BIAFBioAffinity Technologies Sees FY25 Revenue $6M-$8M.
BIAFBioAFfinity Technologies FY24 EPS (0.75) Up From ($0.91) YoY; Revenue $9.4 million Up From $2.5 Million YoY
BIAFbioAffinity Technologies Releases Case Study For CyPath Lung
BIAFBioAffinity Technologies Announces CyPath Lung Study Identifying Breast Cancer Recurrence In 80-Year-Old, Highlighting Oncological Care Potential
BIAF12 Health Care Stocks Moving In Monday's Intraday Session
BIAFbioAffinity Technologies Announces Targeted Strategic Actions To Improve Financial Performance And Accelerate The Commercial Growth Of CyPath Lung; Expects These Measures To Deliver ~$4M In Annual Cost Savings
BIAFBioAffinity Technologies Announced CyPath Lung Beta Launch in Texas With 600+ Tests Sold in 2024
BIAFbioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States
BIAFWhy BioAffinity Technologies Shares Are Skyrocketing
BIAFBioAffinity Technologies Inc (NASDAQ: BIAF) shares are trading higher by 15.5% to $4.78 during Wednesday's trading session after the company announced publication of its research in high-throughput flow cytometry analysis of sputum in PLOS ONE.
What Else?
BioAffinity Technologies Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 53%
BIAFBioAffinity Technologies Shares Halted On Circuit Breaker
BIAFBioAffinity Technologies Publishes Peer-Reviewed Results Of High-Throughput Flow Cytometry Use For Evaluating Lung Health In PLOS ONE Journal; Shares Spike Higher
BIAF